{"id":1193,"date":"2020-05-19T07:55:17","date_gmt":"2020-05-19T07:55:17","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=1193"},"modified":"2023-08-29T17:45:19","modified_gmt":"2023-08-29T17:45:19","slug":"amplia-therapeutics-second-orphan-drug-designation-treatment-chronic-lung-disease","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=1193","title":{"rendered":"Amplia Therapeutics\u83b7\u5f97\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u7269\u6307\u5b9a\uff0c\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u80ba\u75c5"},"content":{"rendered":"<p>\u5236\u836f\u516c\u53f8<a href=\"http:\/\/smallcaps-production.test\/stocks\/?symbol=ATX&amp;lang=cn\">Amplia Therapeutics (ASX: ATX)<\/a>\u56e0\u5176\u5c40\u7076\u6027\u7c98\u9644\u6fc0\u9176\u6291\u5236\u5242AMP945\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40\u7684\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u6307\u5b9a\u3002<\/p>\n<p>AMP945\u88ab\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u88ab\u79f0\u4e3a\u7279\u53d1\u6027\u80ba\u7ea4\u7ef4\u5316\u7684\u6162\u6027\u80ba\u90e8\u75be\u75c5\uff0c\u8fd9\u610f\u5473\u7740Amplia\u5c06\u6709\u8d44\u683c\u83b7\u5f97FDA\u514d\u9664\u8d39\u7528\uff0c\u4e34\u5e8a\u8bd5\u9a8c\u65b9\u6848\u63f4\u52a9\u548c\u5176\u4ed6\u5956\u52b1\u3002<\/p>\n<p>\u6b64\u5916\uff0c\u5982\u679cAmplia\u786e\u4fdd\u7f8e\u56fdAMP945\u6cbb\u7597\u7279\u53d1\u6027\u80ba\u7ea4\u7ef4\u5316\u7684\u76d1\u7ba1\u8bb8\u53ef\uff0c\u8be5\u836f\u7269\u5c06\u6709\u8d44\u683c\u5728FDA\u7ba1\u7406\u7684\u5e02\u573a7\u5e74\u7684\u6392\u4ed6\u6027\u3002<\/p>\n<h2>\u7b2c\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c<\/h2>\n<p>Amplia\u516c\u53f8\u8463\u4e8b\u603b\u7ecf\u7406John Lambert\u535a\u58eb\u8868\u793a\uff0c\u8be5\u516c\u53f8\u5c06\u5728\u4eca\u5e74\u665a\u4e9b\u65f6\u5019\u5f00\u59cb\u5728\u5065\u5eb7\u5fd7\u613f\u8005\u4e2d\u8fdb\u884c\u7b2c\u4e00\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u4ee5\u8bc1\u5b9e\u8be5\u836f\u7269\u7684\u8010\u53d7\u6027\u826f\u597d\u3002<\/p>\n<p>\u4ed6\u8bf4:\u201c\u8fd9\u4e00\u8ba4\u5b9a\u8fdb\u4e00\u6b65\u8bc1\u5b9e\u4e86\u6211\u4eec\u6b63\u5728\u4e3a\u6211\u4eec\u7684\u4e13\u5229\u5c40\u7076\u6027\u7c98\u9644\u6fc0\u9176\u6291\u5236\u5242\u63d0\u4f9b\u66f4\u591a\u7684\u673a\u4f1a\u3002\u201d<\/p>\n<p>\u201c\u7b2c\u4e00\u9636\u6bb5\u5c06\u63d0\u4f9b\u5b89\u5168\u6027\u3001\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u63a2\u7d22\u6027\u836f\u6548\u5b66\u6570\u636e\uff0c\u4f7fAMP945\u5728\u660e\u5e74\u8fdb\u5165\u764c\u75c7\u548c\u7279\u53d1\u6027\u80ba\u7ea4\u7ef4\u5316\u60a3\u8005\u7684\u7b2c\u4e8c\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u3002\u201d<\/p>\n<h2>\u6ca1\u6709\u4efb\u4f55\u5df2\u77e5\u7684\u539f\u56e0<\/h2>\n<p>\u7279\u53d1\u6027(\u6216\u201c\u672a\u77e5\u539f\u56e0\u201d)\u80ba\u7ea4\u7ef4\u5316\u662f\u4e00\u79cd\u7f55\u89c1\u7684\u75be\u75c5\uff0c\u5b83\u4f1a\u5bfc\u81f4\u80ba\u6c14\u56ca(\u6216\u80ba\u6ce1)\u5468\u56f4\u7684\u7ec4\u7ec7\u53d8\u539a\u5e76\u7559\u4e0b\u75a4\u75d5\u3002<\/p>\n<p>\u75a4\u75d5\u4f7f\u80ba\u90e8\u53d8\u786c\uff0c\u8fd9\u4f7f\u5f97\u75c5\u4eba\u8d8a\u6765\u8d8a\u96be\u4ee5\u6df1\u547c\u5438\uff0c\u5e76\u51cf\u6162\u4e86\u8840\u6db2\u4e2d\u6c27\u6c14\u7684\u8f93\u9001\u901f\u5ea6\uff0c\u4ee5\u4fbf\u5c06\u6c27\u6c14\u8f93\u9001\u5230\u8eab\u4f53\u7684\u5176\u4ed6\u90e8\u4f4d\u3002<\/p>\n<p>\u636e\u4f30\u8ba1\uff0c\u7279\u53d1\u6027\u80ba\u7ea4\u7ef4\u5316\u5728\u7f8e\u56fd\u5f71\u54cd\u8d85\u8fc713\u4e07\u4eba\uff0c\u5728\u5168\u4e16\u754c\u5f71\u54cd\u8d85\u8fc7300\u4e07\u4eba\u3002<\/p>\n<p>\u5982\u679c\u4e0d\u53ca\u65f6\u6cbb\u7597\uff0c\u8be5\u75c5\u53ef\u5bf9\u60a3\u8005\u7684\u751f\u6d3b\u8d28\u91cf\u4ea7\u751f\u91cd\u5927\u5f71\u54cd\uff0c\u4e2d\u4f4d\u9884\u540e\u53ef\u8fbe5\u5e74\u3002<\/p>\n<p>Pirfenidone\u548cnintedanib\u662f\u8fc4\u4eca\u4e3a\u6b62\u4ec5\u6709\u7684\u4e24\u79cd\u5df2\u83b7\u6279\u51c6\u4f7f\u7528\u7684\u836f\u7269\uff0c\u5c3d\u7ba1\u5b83\u4eec\u53ef\u4ee5\u5c06\u75be\u75c5\u7684\u8fdb\u5c55\u901f\u5ea6\u51cf\u7f1350%\uff0c\u4f46\u5b83\u4eec\u65e0\u6cd5\u6c38\u4e45\u6cbb\u7597\u75be\u75c5\u3002<\/p>\n<p>\u5728\u4f7f\u7528\u884c\u4e1a\u6807\u51c6\u7684\u5316\u5b66\u8bf1\u5bfc\u80ba\u7ea4\u7ef4\u5316\u6a21\u578b\u7684\u4e34\u5e8a\u524d\u7814\u7a76\u4e2d\uff0cAMP945\u6210\u529f\u5730\u51cf\u5c11\u548c\u9006\u8f6c\u4e86\u7ea4\u7ef4\u5316(\u6216\u786c\u5316)\u7ec4\u7ec7\u7684\u5f62\u6210\u3002<\/p>\n<h2>\u884c\u4e3a\u6a21\u5f0f<\/h2>\n<p>AMP945\u4f5c\u4e3aAmplia\u7684\u5148\u5bfc\u836f\u7269\u5019\u9009\uff0c\u6709\u591a\u79cd\u4f5c\u7528\u6a21\u5f0f\uff0c\u9002\u5408\u4e8e\u5408\u5e76\u5230\u5177\u6709\u6311\u6218\u6027\u7684\u764c\u75c7\u6cbb\u7597\u65b9\u6848\u4e2d\uff0c\u5982\u5f71\u54cd\u80f0\u817a\u3001\u5375\u5de2\u3001\u4e73\u623f\u548c\u80ba\u7684\u764c\u75c7\u3002<\/p>\n<p>\u4eca\u5e743\u6708\uff0cAmplia\u516c\u53f8\u83b7\u5f97\u4e86\u7b2c\u4e00\u4e2a\u5b64\u513f\u836f\u7269AMP945\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u764c\u3002<\/p>\n<p>\u5f53\u65f6\u5bf9\u5176\u5728\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40\u7684\u7533\u8bf7\u7684\u5feb\u901f\u5ba1\u67e5\u7a81\u51fa\u4e86\u5bf9\u65b0\u7684\u6cbb\u7597\u9009\u62e9\u7684\u8ba4\u8bc6\uff0c\u4ee5\u5bf9\u6297\u81f4\u547d\u7684\u75be\u75c5\u7684\u9700\u8981\u3002<\/p>\n<p>\u540c\u4e00\u4e2a\u6708\uff0cAmplia\u516c\u53f8\u63d0\u51fa\u4e86\u4e00\u9879\u56fd\u9645\u4e13\u5229\u7533\u8bf7\uff0c\u6db5\u76d6\u4e86AMP945\u7684\u9996\u9009\u76d0\u5f62\u5f0f\uff0c\u5c06\u5728\u672a\u6765\u7684\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u4f7f\u7528\u3002<\/p>\n<p>\u5982\u679c\u83b7\u5f97\u6279\u51c6\uff0c\u8be5\u7533\u8bf7\u5c06\u4e3aAMP945\u63d0\u4f9b\u989d\u5916\u7684\u4e13\u5229\u8986\u76d6\u8303\u56f4\uff0c\u76f4\u81f32039\u5e74\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u56e0\u5176\u5c40\u7076\u6027\u7c98\u9644\u6fc0\u9176\u6291\u5236\u5242AMP945\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40\u7684\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u6307\u5b9a\u3002 AMP945\u88ab\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u88ab\u79f0\u4e3a\u7279\u53d1\u6027\u80ba\u7ea4\u7ef4\u5316\u7684\u6162\u6027\u80ba\u90e8\u75be\u75c5\uff0c\u8fd9\u610f\u5473\u7740Amplia\u5c06\u6709\u8d44\u683c\u83b7\u5f97FDA\u514d\u9664\u8d39\u7528\uff0c\u4e34\u5e8a\u8bd5\u9a8c\u65b9\u6848\u63f4\u52a9\u548c\u5176\u4ed6\u5956\u52b1\u3002 \u6b64\u5916\uff0c\u5982\u679cAmplia\u786e\u4fdd\u7f8e\u56fdAMP945\u6cbb\u7597\u7279\u53d1\u6027\u80ba\u7ea4\u7ef4\u5316\u7684\u76d1\u7ba1\u8bb8\u53ef\uff0c\u8be5\u836f\u7269\u5c06\u6709\u8d44\u683c\u5728FDA\u7ba1\u7406\u7684\u5e02\u573a7\u5e74\u7684\u6392\u4ed6\u6027\u3002 \u7b2c\u4e00\u671f\u4e34\u5e8a\u8bd5\u9a8c Amplia\u516c\u53f8\u8463\u4e8b\u603b\u7ecf\u7406John Lambert\u535a\u58eb\u8868\u793a\uff0c\u8be5\u516c\u53f8\u5c06\u5728\u4eca\u5e74\u665a\u4e9b\u65f6\u5019\u5f00\u59cb\u5728\u5065\u5eb7\u5fd7\u613f\u8005\u4e2d\u8fdb\u884c\u7b2c\u4e00\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u4ee5\u8bc1\u5b9e\u8be5\u836f\u7269\u7684\u8010\u53d7\u6027\u826f\u597d\u3002 \u4ed6\u8bf4:\u201c\u8fd9\u4e00\u8ba4\u5b9a\u8fdb\u4e00\u6b65\u8bc1\u5b9e\u4e86\u6211\u4eec\u6b63\u5728\u4e3a\u6211\u4eec\u7684\u4e13\u5229\u5c40\u7076\u6027\u7c98\u9644\u6fc0\u9176\u6291\u5236\u5242\u63d0\u4f9b\u66f4\u591a\u7684\u673a\u4f1a\u3002\u201d \u201c\u7b2c\u4e00\u9636\u6bb5\u5c06\u63d0\u4f9b\u5b89\u5168\u6027\u3001\u836f\u4ee3\u52a8\u529b\u5b66\u548c\u63a2\u7d22\u6027\u836f\u6548\u5b66\u6570\u636e\uff0c\u4f7fAMP945\u5728\u660e\u5e74\u8fdb\u5165\u764c\u75c7\u548c\u7279\u53d1\u6027\u80ba\u7ea4\u7ef4\u5316\u60a3\u8005\u7684\u7b2c\u4e8c\u9636\u6bb5\u4e34\u5e8a\u8bd5\u9a8c\u3002\u201d \u6ca1\u6709\u4efb\u4f55\u5df2\u77e5\u7684\u539f\u56e0 \u7279\u53d1\u6027(\u6216\u201c\u672a\u77e5\u539f\u56e0\u201d)\u80ba\u7ea4\u7ef4\u5316\u662f\u4e00\u79cd\u7f55\u89c1\u7684\u75be\u75c5\uff0c\u5b83\u4f1a\u5bfc\u81f4\u80ba\u6c14\u56ca(\u6216\u80ba\u6ce1)\u5468\u56f4\u7684\u7ec4\u7ec7\u53d8\u539a\u5e76\u7559\u4e0b\u75a4\u75d5\u3002 \u75a4\u75d5\u4f7f\u80ba\u90e8\u53d8\u786c\uff0c\u8fd9\u4f7f\u5f97\u75c5\u4eba\u8d8a\u6765\u8d8a\u96be\u4ee5\u6df1\u547c\u5438\uff0c\u5e76\u51cf\u6162\u4e86\u8840\u6db2\u4e2d\u6c27\u6c14\u7684\u8f93\u9001\u901f\u5ea6\uff0c\u4ee5\u4fbf\u5c06\u6c27\u6c14\u8f93\u9001\u5230\u8eab\u4f53\u7684\u5176\u4ed6\u90e8\u4f4d\u3002 \u636e\u4f30\u8ba1\uff0c\u7279\u53d1\u6027\u80ba\u7ea4\u7ef4\u5316\u5728\u7f8e\u56fd\u5f71\u54cd\u8d85\u8fc713\u4e07\u4eba\uff0c\u5728\u5168\u4e16\u754c\u5f71\u54cd\u8d85\u8fc7300\u4e07\u4eba\u3002 \u5982\u679c\u4e0d\u53ca\u65f6\u6cbb\u7597\uff0c\u8be5\u75c5\u53ef\u5bf9\u60a3\u8005\u7684\u751f\u6d3b\u8d28\u91cf\u4ea7\u751f\u91cd\u5927\u5f71\u54cd\uff0c\u4e2d\u4f4d\u9884\u540e\u53ef\u8fbe5\u5e74\u3002 Pirfenidone\u548cnintedanib\u662f\u8fc4\u4eca\u4e3a\u6b62\u4ec5\u6709\u7684\u4e24\u79cd\u5df2\u83b7\u6279\u51c6\u4f7f\u7528\u7684\u836f\u7269\uff0c\u5c3d\u7ba1\u5b83\u4eec\u53ef\u4ee5\u5c06\u75be\u75c5\u7684\u8fdb\u5c55\u901f\u5ea6\u51cf\u7f1350%\uff0c\u4f46\u5b83\u4eec\u65e0\u6cd5\u6c38\u4e45\u6cbb\u7597\u75be\u75c5\u3002 \u5728\u4f7f\u7528\u884c\u4e1a\u6807\u51c6\u7684\u5316\u5b66\u8bf1\u5bfc\u80ba\u7ea4\u7ef4\u5316\u6a21\u578b\u7684\u4e34\u5e8a\u524d\u7814\u7a76\u4e2d\uff0cAMP945\u6210\u529f\u5730\u51cf\u5c11\u548c\u9006\u8f6c\u4e86\u7ea4\u7ef4\u5316(\u6216\u786c\u5316)\u7ec4\u7ec7\u7684\u5f62\u6210\u3002 \u884c\u4e3a\u6a21\u5f0f AMP945\u4f5c\u4e3aAmplia\u7684\u5148\u5bfc\u836f\u7269\u5019\u9009\uff0c\u6709\u591a\u79cd\u4f5c\u7528\u6a21\u5f0f\uff0c\u9002\u5408\u4e8e\u5408\u5e76\u5230\u5177\u6709\u6311\u6218\u6027\u7684\u764c\u75c7\u6cbb\u7597\u65b9\u6848\u4e2d\uff0c\u5982\u5f71\u54cd\u80f0\u817a\u3001\u5375\u5de2\u3001\u4e73\u623f\u548c\u80ba\u7684\u764c\u75c7\u3002 \u4eca\u5e743\u6708\uff0cAmplia\u516c\u53f8\u83b7\u5f97\u4e86\u7b2c\u4e00\u4e2a\u5b64\u513f\u836f\u7269AMP945\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u764c\u3002 \u5f53\u65f6\u5bf9\u5176\u5728\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40\u7684\u7533\u8bf7\u7684\u5feb\u901f\u5ba1\u67e5\u7a81\u51fa\u4e86\u5bf9\u65b0\u7684\u6cbb\u7597\u9009\u62e9\u7684\u8ba4\u8bc6\uff0c\u4ee5\u5bf9\u6297\u81f4\u547d\u7684\u75be\u75c5\u7684\u9700\u8981\u3002 \u540c\u4e00\u4e2a\u6708\uff0cAmplia\u516c\u53f8\u63d0\u51fa\u4e86\u4e00\u9879\u56fd\u9645\u4e13\u5229\u7533\u8bf7\uff0c\u6db5\u76d6\u4e86AMP945\u7684\u9996\u9009\u76d0\u5f62\u5f0f\uff0c\u5c06\u5728\u672a\u6765\u7684\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u4f7f\u7528\u3002 \u5982\u679c\u83b7\u5f97\u6279\u51c6\uff0c\u8be5\u7533\u8bf7\u5c06\u4e3aAMP945\u63d0\u4f9b\u989d\u5916\u7684\u4e13\u5229\u8986\u76d6\u8303\u56f4\uff0c\u76f4\u81f32039\u5e74\u3002<\/p>\n","protected":false},"author":4,"featured_media":7893,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[58],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Amplia Therapeutics\u83b7\u5f97\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u7269\u6307\u5b9a\uff0c\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u80ba\u75c5<\/title>\n<meta name=\"description\" content=\"\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u56e0\u5176\u5c40\u7076\u6027\u7c98\u9644\u6fc0\u9176\u6291\u5236\u5242AMP945\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40\u7684\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u6307\u5b9a\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amplia Therapeutics\u83b7\u5f97\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u7269\u6307\u5b9a\uff0c\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u80ba\u75c5\" \/>\n<meta property=\"og:description\" content=\"\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u56e0\u5176\u5c40\u7076\u6027\u7c98\u9644\u6fc0\u9176\u6291\u5236\u5242AMP945\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40\u7684\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u6307\u5b9a\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-second-orphan-drug-designation-treatment-chronic-lung-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-19T07:55:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:45:19+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/05\/Amplia-Therapeutics-ASX-ATX-FDA-Orphan-Drug-Designation-Idiopathic-Pulmonary-Fibrosis.jpg\" \/>\n<meta name=\"author\" content=\"Imelda Cotton\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Amplia Therapeutics\u83b7\u5f97\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u7269\u6307\u5b9a\uff0c\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u80ba\u75c5\" \/>\n<meta name=\"twitter:description\" content=\"\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u56e0\u5176\u5c40\u7076\u6027\u7c98\u9644\u6fc0\u9176\u6291\u5236\u5242AMP945\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40\u7684\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u6307\u5b9a\u3002\" \/>\n<meta name=\"twitter:image\" content=\"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/05\/Amplia-Therapeutics-ASX-ATX-FDA-Orphan-Drug-Designation-Idiopathic-Pulmonary-Fibrosis.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Imelda Cotton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-second-orphan-drug-designation-treatment-chronic-lung-disease\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-second-orphan-drug-designation-treatment-chronic-lung-disease\/\",\"name\":\"Amplia Therapeutics\u83b7\u5f97\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u7269\u6307\u5b9a\uff0c\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u80ba\u75c5\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2020-05-19T07:55:17+00:00\",\"dateModified\":\"2023-08-29T17:45:19+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\"},\"description\":\"\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u56e0\u5176\u5c40\u7076\u6027\u7c98\u9644\u6fc0\u9176\u6291\u5236\u5242AMP945\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40\u7684\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u6307\u5b9a\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-second-orphan-drug-designation-treatment-chronic-lung-disease\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-second-orphan-drug-designation-treatment-chronic-lung-disease\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-second-orphan-drug-designation-treatment-chronic-lung-disease\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amplia Therapeutics\u83b7\u5f97\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u7269\u6307\u5b9a\uff0c\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u80ba\u75c5\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\",\"name\":\"Imelda Cotton\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"caption\":\"Imelda Cotton\"},\"description\":\"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Amplia Therapeutics\u83b7\u5f97\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u7269\u6307\u5b9a\uff0c\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u80ba\u75c5","description":"\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u56e0\u5176\u5c40\u7076\u6027\u7c98\u9644\u6fc0\u9176\u6291\u5236\u5242AMP945\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40\u7684\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u6307\u5b9a\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Amplia Therapeutics\u83b7\u5f97\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u7269\u6307\u5b9a\uff0c\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u80ba\u75c5","og_description":"\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u56e0\u5176\u5c40\u7076\u6027\u7c98\u9644\u6fc0\u9176\u6291\u5236\u5242AMP945\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40\u7684\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u6307\u5b9a\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-second-orphan-drug-designation-treatment-chronic-lung-disease\/","og_site_name":"smallcapsCN","article_published_time":"2020-05-19T07:55:17+00:00","article_modified_time":"2023-08-29T17:45:19+00:00","og_image":[{"url":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/05\/Amplia-Therapeutics-ASX-ATX-FDA-Orphan-Drug-Designation-Idiopathic-Pulmonary-Fibrosis.jpg"}],"author":"Imelda Cotton","twitter_card":"summary_large_image","twitter_title":"Amplia Therapeutics\u83b7\u5f97\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u7269\u6307\u5b9a\uff0c\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u80ba\u75c5","twitter_description":"\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u56e0\u5176\u5c40\u7076\u6027\u7c98\u9644\u6fc0\u9176\u6291\u5236\u5242AMP945\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40\u7684\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u6307\u5b9a\u3002","twitter_image":"http:\/\/smallcaps-production.test\/wp-content\/uploads\/2020\/05\/Amplia-Therapeutics-ASX-ATX-FDA-Orphan-Drug-Designation-Idiopathic-Pulmonary-Fibrosis.jpg","twitter_misc":{"Written by":"Imelda Cotton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-second-orphan-drug-designation-treatment-chronic-lung-disease\/","url":"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-second-orphan-drug-designation-treatment-chronic-lung-disease\/","name":"Amplia Therapeutics\u83b7\u5f97\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u7269\u6307\u5b9a\uff0c\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u80ba\u75c5","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2020-05-19T07:55:17+00:00","dateModified":"2023-08-29T17:45:19+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e"},"description":"\u5236\u836f\u516c\u53f8Amplia Therapeutics (ASX: ATX)\u56e0\u5176\u5c40\u7076\u6027\u7c98\u9644\u6fc0\u9176\u6291\u5236\u5242AMP945\u83b7\u5f97\u4e86\u7f8e\u56fd\u98df\u54c1\u548c\u836f\u7269\u7ba1\u7406\u5c40\u7684\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u6307\u5b9a\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-second-orphan-drug-designation-treatment-chronic-lung-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-second-orphan-drug-designation-treatment-chronic-lung-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/amplia-therapeutics-second-orphan-drug-designation-treatment-chronic-lung-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Amplia Therapeutics\u83b7\u5f97\u7b2c\u4e8c\u4e2a\u5b64\u513f\u836f\u7269\u6307\u5b9a\uff0c\u7528\u4e8e\u6cbb\u7597\u6162\u6027\u80ba\u75c5"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e","name":"Imelda Cotton","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","caption":"Imelda Cotton"},"description":"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.","url":"https:\/\/smallcapscn.x5view.co\/?author=4"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1193"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1193"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1193\/revisions"}],"predecessor-version":[{"id":7892,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/1193\/revisions\/7892"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/7893"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}